Yusuf Hameed/LinkedIn
May 23, 2026, 16:44
Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
Yusuf Hameed, Anesthesiologist, Principal of Angel Investor, shared a post on X:
“Promising news for hemophilia A patients:
Many patients in Sangamo Therapeutics‘ giroctocogene fitelparvovec trials maintain strong benefits (fewer bleeds, lower treatment burden) through approximately 3-4 years of follow-up—a real advance vs lifelong prophylaxis.
Long-term (5-10+ years) data is still maturing, with individual results varying.
Big upside:
One-time gene therapy could yield major lifetime cost savings vs $300K–$800K+/yr prophylaxis (often more than $20M lifetime). Screening plus monitoring key.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow
-
May 23, 2026, 16:19Sitthiwut Chaturamaytanon: 6 Days Advancing aHUS and PNH Care in Thailand Through Collaboration